Logo image of VALN

VALNEVA SE - ADR (VALN) Stock Fundamental Analysis

NASDAQ:VALN - Nasdaq - US92025Y1038 - ADR - Currency: USD

7.87  +0.37 (+4.93%)

After market: 8.02 +0.15 (+1.91%)

Fundamental Rating

3

Overall VALN gets a fundamental rating of 3 out of 10. We evaluated VALN against 551 industry peers in the Biotechnology industry. VALN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, VALN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

VALN had negative earnings in the past year.
In the past year VALN has reported a negative cash flow from operations.
VALN had negative earnings in each of the past 5 years.
In multiple years VALN reported negative operating cash flow during the last 5 years.
VALN Yearly Net Income VS EBIT VS OCF VS FCFVALN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

VALN's Return On Assets of 7.48% is amongst the best of the industry. VALN outperforms 93.28% of its industry peers.
The Return On Equity of VALN (20.65%) is better than 96.19% of its industry peers.
Industry RankSector Rank
ROA 7.48%
ROE 20.65%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
VALN Yearly ROA, ROE, ROICVALN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

VALN has a Profit Margin of 15.08%. This is amongst the best in the industry. VALN outperforms 93.83% of its industry peers.
The Gross Margin of VALN (41.01%) is better than 74.59% of its industry peers.
VALN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 15.08%
GM 41.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
VALN Yearly Profit, Operating, Gross MarginsVALN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

3

2. Health

2.1 Basic Checks

VALN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VALN has more shares outstanding
Compared to 5 years ago, VALN has more shares outstanding
Compared to 1 year ago, VALN has an improved debt to assets ratio.
VALN Yearly Shares OutstandingVALN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VALN Yearly Total Debt VS Total AssetsVALN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

VALN has an Altman-Z score of 0.47. This is a bad value and indicates that VALN is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 0.47, VALN is doing good in the industry, outperforming 63.70% of the companies in the same industry.
A Debt/Equity ratio of 1.06 is on the high side and indicates that VALN has dependencies on debt financing.
VALN has a worse Debt to Equity ratio (1.06) than 77.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Altman-Z 0.47
ROIC/WACCN/A
WACC7.99%
VALN Yearly LT Debt VS Equity VS FCFVALN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

VALN has a Current Ratio of 2.61. This indicates that VALN is financially healthy and has no problem in meeting its short term obligations.
VALN has a Current ratio of 2.61. This is in the lower half of the industry: VALN underperforms 68.60% of its industry peers.
VALN has a Quick Ratio of 2.14. This indicates that VALN is financially healthy and has no problem in meeting its short term obligations.
VALN's Quick ratio of 2.14 is on the low side compared to the rest of the industry. VALN is outperformed by 72.05% of its industry peers.
Industry RankSector Rank
Current Ratio 2.61
Quick Ratio 2.14
VALN Yearly Current Assets VS Current LiabilitesVALN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

VALN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -184.21%.
The Revenue has grown by 17.86% in the past year. This is quite good.
Measured over the past years, VALN shows a small growth in Revenue. The Revenue has been growing by 6.09% on average per year.
EPS 1Y (TTM)-184.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.63%
Revenue 1Y (TTM)17.86%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%50.31%

3.2 Future

The Earnings Per Share is expected to grow by 119.91% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 24.84% on average over the next years. This is a very strong growth
EPS Next Y-597.38%
EPS Next 2Y-69.87%
EPS Next 3Y119.91%
EPS Next 5YN/A
Revenue Next Year6.79%
Revenue Next 2Y15.57%
Revenue Next 3Y28.62%
Revenue Next 5Y24.84%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VALN Yearly Revenue VS EstimatesVALN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
VALN Yearly EPS VS EstimatesVALN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VALN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VALN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VALN Price Earnings VS Forward Price EarningsVALN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VALN Per share dataVALN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as VALN's earnings are expected to grow with 119.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-69.87%
EPS Next 3Y119.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VALN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALNEVA SE - ADR

NASDAQ:VALN (8/5/2025, 7:20:53 PM)

After market: 8.02 +0.15 (+1.91%)

7.87

+0.37 (+4.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners23.31%
Inst Owner Change-1.86%
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap669.20M
Analysts83.64
Price Target16.62 (111.18%)
Short Float %0.03%
Short Ratio0.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-31.52%
Min EPS beat(2)-115.24%
Max EPS beat(2)52.2%
EPS beat(4)2
Avg EPS beat(4)-8.58%
Min EPS beat(4)-115.24%
Max EPS beat(4)72.74%
EPS beat(8)4
Avg EPS beat(8)-10.16%
EPS beat(12)5
Avg EPS beat(12)-55.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.5%
Min Revenue beat(2)-4.78%
Max Revenue beat(2)1.77%
Revenue beat(4)1
Avg Revenue beat(4)-7.74%
Min Revenue beat(4)-14.39%
Max Revenue beat(4)1.77%
Revenue beat(8)4
Avg Revenue beat(8)-2.47%
Revenue beat(12)6
Avg Revenue beat(12)43.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.73%
PT rev (3m)2.06%
EPS NQ rev (1m)11.18%
EPS NQ rev (3m)11.18%
EPS NY rev (1m)0%
EPS NY rev (3m)11.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)0.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.33
P/FCF N/A
P/OCF N/A
P/B 3.19
P/tB 3.71
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS3.38
BVpS2.47
TBVpS2.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.48%
ROE 20.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 15.08%
GM 41.01%
FCFM N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.96%
Cap/Sales 6.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.61
Quick Ratio 2.14
Altman-Z 0.47
F-Score5
WACC7.99%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.63%
EPS Next Y-597.38%
EPS Next 2Y-69.87%
EPS Next 3Y119.91%
EPS Next 5YN/A
Revenue 1Y (TTM)17.86%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%50.31%
Revenue Next Year6.79%
Revenue Next 2Y15.57%
Revenue Next 3Y28.62%
Revenue Next 5Y24.84%
EBIT growth 1Y82.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-262.99%
EBIT Next 3Y35.74%
EBIT Next 5Y30.38%
FCF growth 1Y61.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.85%
OCF growth 3YN/A
OCF growth 5YN/A